India Tarceva purchase 13621079267 India Tarceva manufacturer efficacy

d%> d= _ d=> Selecting suitable lung cancer patients based on r mutation status and receiving
Indian Tarceva> treatment is expected to make lung cancer treatment more individualized. Hailed as one of the most important discoveries in lung cancer research in recent years, it was determined that the target population of the tyrosine kinase inhibitor gefitinib is non-smoking adenocarcinoma patients in the Eastern population.
Our research suggests that the r mutation rate of Chinese lung adenocarcinoma is .% much higher than the .%(.) of other types of lung cancer. At the annual meeting of the American Society of Clinical Oncology in 2017, the first prospective randomized controlled clinical study of chemotherapy regimen selection based on molecular marker classification was presented. The low-expression group had a .% response rate to the cisplatin-containing Tarceva regimen. The highest response rate. Unfortunately, the r high expression group only had an effective rate of .% against the non-platinum regimen and did not show efficient results. .d/
The word tailor-made has been frequently used together with chemotherapy. In fact, the clinical factors of Eastern population, female gender, non-smoking, and adenocarcinoma can be attributed to the unique molecular biological characteristics of r mutation. The basis of tailor-made chemotherapy is the selection of chemotherapy regimens based on biomarkers. Of interest in the field of lung cancer is the relationship between r and cisplatin, r and gemcitabine, and -and the taxane Tarceva.
The uniqueness of each individual lies in its unique genetic profile.
Personalized treatment of lung cancer based on functional genomics and proteomics may allow us to design a unique treatment plan with the best effect and the lowest toxic and side effects for each lung cancer patient.
The patients all underwent complete resection and were supplemented with Indian Tarceva cycle chemotherapy. The results showed that the median recurrence-free time in the -Ⅲ positive group was only months, while in the negative group it was months (=.) There were .% patients in the adjuvant chemotherapy ineffective group -Ⅲ positive expression was significantly higher than .% in the adjuvant chemotherapy effective group ( =.).
Overexpression of the Donacet gene - Implicates the response to Doxorubicin and Paclitaxel.
Do we have reason to believe that the era of personalized treatment of cancer is coming soon? In fact, there is still a huge gap between the research results of laboratory and clinical small samples and clinical application. It is not easy to cross this gap. Therefore, under the current circumstances, it is not appropriate to easily generalize and apply the preliminary knowledge gained to clinical practice. It can be said that there are pitfalls and solutions everywhere in personalized cancer treatment. The key lies in how to bridge the gap between laboratory and clinical practice.
In addition, the polymorphism of r also determines the properties of gemcitabine and its properties.
The research results of functional genomics are dazzling.
Our phase III clinical randomized controlled trial of adjuvant chemotherapy explored the value of -III in predicting the efficacy of postoperative adjuvant chemotherapy.